A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Clinical trial NCT04106219 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04106219
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-11
- Primary completion
- 2022-04-13
- Enrollment
- 71
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.